Antibody Drug Conjugates (ADC) Size, Share & Trends Analysis Report 2024: Global Market to Surpass $24 Billion by 2030, Driven by a Strong Product Pipeline & Rising Incidence and Prevalence Of Cancer
13 mai 2024 10h22 HE
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable,...
Antibody-Drug Conjugates (ADC) Industry Overview 2024: Market to Exceed $40 Billion by 2029, Driven by Daiichi Sankyo's Enhertu, Roche's Kadcyla, Astellas Pharma, Pfizer's Padcev, & Gilead's Trodelvy
26 avr. 2024 06h59 HE
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates (ADC): Market Overview" report has been added to ResearchAndMarkets.com's offering. The global ADC market grew from $50...
Global Single-use Assemblies Market Projected to Surge to USD 39.97 Billion by 2030
29 mars 2024 05h35 HE
|
Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Global Single-use Assemblies Market Size, Share & Trends Analysis Report by Product (Bag Assemblies, Filtration Assemblies), Application...
ADC Contract Manufacturing Market projected to reach USD 27.4 Billion by 2030, growing at a CAGR of 14.2% during the forecast period of 2023-2030 - a comprehensive study by MarketDigits
05 mars 2024 08h00 HE
|
PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED
Richmond, March 05, 2024 (GLOBE NEWSWIRE) -- According to a research report "ADC Contract Manufacturing Market”, by Linker (Cleavable Linker, Non-Cleavable Linkers, and Others), Application...
Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
15 févr. 2024 11h45 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...
BioNTech und DualityBio starten zulassungsrelevante Phase-3-Studie mit Antikörper-Wirkstoff-Konjugat-Kandidat BNT323/DB-1303 bei metastasiertem Brustkrebs
22 janv. 2024 06h45 HE
|
BioNTech SE
Der Start der zulassungsrelevanten Phase-3-Studie mit BNT323/DB-1303 basiert auf positiven Daten zur Sicherheit und Wirksamkeit aus einer Phase-1/2-Studie bei Brustkrebspatientinnen und -patienten mit...
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22 janv. 2024 06h45 HE
|
BioNTech SE
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors...
Immunotherapy Targeting Mesothelin: A Comprehensive 2023 Pipeline Review
14 déc. 2023 05h43 HE
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Mesothelin-Targeted Immunotherapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. A groundbreaking review of...
Folate Receptor Alpha Targeted Therapies - Exciting Advancements in Oncological R&D Revealed in Comprehensive Pipeline Review
14 déc. 2023 05h28 HE
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Folate Receptor alpha (FRa) Targeted Therapy Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This pipeline review...
Anti-CD38 Antibody Pipeline Research Report 2023 Featuring Sorrento Therapeutics, I-MAB Biopharma, Takeda, Hangzhou Sumgen Biotech, Wuhan YZY Biopharma, and Biomunex Pharmaceuticals
22 nov. 2023 08h38 HE
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Anti-CD38 antibody - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...